LUCD logo

LUCID DIAGNOSTICS INC

LUCDNASDAQ
🏆 #4016 by market capUS Equity
——
Quote unavailable
🔔
Track LUCD
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$89M
Small Cap
📈Revenue Growth (YoY)
24.9%
Healthy
📊Gross Margin
-21.7%
Thin
💵FCF Margin
—
⚖️P/S Ratio
16.4x
Expensive
Otter Score
—
Insufficient data
No chart data available for LUCD.

Trading Snapshot

Day Range
—
52-Week Range
$0.30 – $1.63
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
190.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$5M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
16.4x
EPS (TTM)
$-0.38
Dividend Yield
—
Dilution (1yr)
+76.7%
LUCD logo

LUCID DIAGNOSTICS INC

LUCD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5M▲ +8.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-60.3%▼ −33.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$50M▲ +7.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$46M▲ +3.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
101.9M▲ +76.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$34.7B▲ +$34.7B YoY
StockOtter · stockotter.space

About LUCID DIAGNOSTICS INC

Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.